je.st

Home › cancer

Tag: cancer

Midas take on a challenge of a different kind for Macmillan Cancer Support

2017-06-19 11:58:34| RSS Site News

Midas are pleased to announce that their charity of the year for 2008 is Macmillan Cancer Support.

Tags: support kind challenge cancer

06.01.12 -- FDA-Approved Drug Makes Established Cancer Vaccine Work Better

2017-02-08 08:29:03| drugdiscoveryonline News Articles

06/01/12 Drug Discovery Online Newsletter

Tags: work better makes established

Pureology Renews Partnership with National Ovarian Cancer Coalition

2017-02-03 18:13:00| Happi Breaking News

$100K donation, digital/social activations and sponsorship of NOCC Run/Walks throughout 2017.

Tags: national partnership cancer coalition

FDA Accepts Two sBLAs for Mercks KEYTRUDA (pembrolizumab) for Locally Advanced or Metastatic Urothelial Cancer in Cisplatin-Ineligible First-Line and Second-Line Post-Platinum Failure Treatment Settings

2017-02-03 12:45:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. KEYTRUDA Also Receives Breakthrough Therapy Designation for Second-Line Treatment Based on KEYNOTE-045, Which Includes Primary Endpoints of Overall Survival and Progression-Free Survival KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental Biologics License Applications (sBLAs) for KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in patients with locally advanced or metastatic urothelial cancer, a type of bladder cancer. Language: English Contact: For MerckMedia:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more

Tags: advanced treatment settings failure